Putting Poetry into a Creative End Product

Mixed Media Art has found a place in the heart of Leeanne Oschmanns as declares that a craving for harmony and balance in her creativity brought up the need to express her poetry in more than words. Merely drawing or painting a picture didn’t work because it was too stifling and usually limited the expressive elements to one aspect of the poem. However, the beauty of poetry is that it is many things and something different to each person and the same can be said of mixed media.

Since Mixed Media is versatile and diverse, the power of symbols and the beauty of texture and medium render a flexibility that is more difficult to achieve in styles of singular medium and subject. Sometimes a thought so profound that it should not pass can be symbolised and articulated with visual richness and subtle suggestion.  This is the single reason why she recently felt encouraged to contemplate the 100th anniversary of The Great War by burning only a single light, preferably a candle, in the darkness. She has this strong urge to express her thoughts.

It is referred to as the power of creativity by use of words.  Her passions include personal growth and understanding. However, people and animals complete her experience of what it is to be human. And being a poet is her way of shedding light on the things that seemed darkest or most beautiful. On the other hand the power of symbols and the beauty of texture and medium render a flexibility that is more difficult to achieve in styles of singular medium and subject.

image

Merck Strengthens Executive Board

DARMSTADT, Germany, September 19, 2014 /PRNewswire/ —

  • Stefan Oschmann appointed Deputy CEO and Vice Chairman of the Executive Board
  • Belen Garijo appointed new member of the Executive Board
  • Changes effective from January 1, 2015

Merck today announced that the Board of Partners has promoted Stefan Oschmann (57) to the position of Deputy CEO and Vice Chairman of the Executive Board. Concurrently, Belen Garijo (54) was appointed to the Executive Board to take over leadership for the Pharma business. The management changes will become effective as of January 1, 2015.

(Photo: http://ift.tt/Xpl6dE )
(Photo: http://ift.tt/1mgPlzv )

Oschmann, currently CEO Pharma, will represent Karl-Ludwig Kley, Chairman of the Executive Board. Both will share strategic management functions and will represent the company with politicians and international organizations.

As a member of the Executive Board, Garijo, currently CEO of Merck’s biopharmaceutical division Merck Serono, will take on responsibility for the whole Pharma business. Besides Merck Serono, this includes Consumer Health, Allergy and Biosimilars.

"With today’s management decisions we strengthen Merck’s leadership team and prepare the ground for continuity to reach our ambitious growth targets until the year 2018 and beyond," said Johannes Baillou, Chairman of the Board of Partners of E. Merck KG. “Stefan Oschmann who has successfully reorganized our pharma businesses over the past years will familiarize himself with Group-wide functions and will increasingly assume external responsibilities for the company. Belen Garijo has many years of experience in the pharma industry, has proven that she can further develop our business organization and in her future role will provide a significant contribution to ensure the sustainable success of our pharma businesses.”

Note to editors

You find pictures and CVs here.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://ift.tt/P4xUC9 to register online, change your selection or discontinue this service.

Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of € 11.1 billion in 2013. Around 39,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of our customers and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company - since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as EMD.



Read this news on PR Newswire Asia website: Merck Strengthens Executive Board
Merck KGaA appoints pharma head Oschmann as deputy CEO



Merck KGaA appoints pharma head Oschmann as deputy CEO

(Reuters) – German drugs and chemicals maker Merck KGaA appointed the head of its pharma business, Stefan Oschmann, as deputy chief executive, it said on Thursday.

Oschmann, 57, will share strategic management functions and representation of the company with CEO Karl-Ludwig Kley as of Jan. 1, 2015, it said.

The promotion puts Oschmann in the frame to possibly succeed Kley, whose contract runs until September 2016.

Belen Garijo, 54, will take over leadership of the entire pharma business, according to the statement. Garijo is already CEO of Merck’s biopharmaceutical division, Merck Serono, to which she will add consumer health, allergy treatments and biosimilars.

(Reporting by Georgina Prodhan; Editing by Ludwig Burger)

Read the original here:
feeds.reuters

Healthy Living News From around The Web
Merck KGaA appoints pharma head Stefan Oschmann as deputy CEO - Economic Times




Google+

Dopps Chiropractic
1611 E 61st St N
Park City, Ks 67219
(316) 744-8228
http://ift.tt/14YaNzI

Merck KGaA appoints pharma head Oschmann as deputy CEO



Merck KGaA appoints pharma head Oschmann as deputy CEO

(Reuters) – German drugs and chemicals maker Merck KGaA appointed the head of its pharma business, Stefan Oschmann, as deputy chief executive, it said on Thursday.

Oschmann, 57, will share strategic management functions and representation of the company with CEO Karl-Ludwig Kley as of Jan. 1, 2015, it said.

The promotion puts Oschmann in the frame to possibly succeed Kley, whose contract runs until September 2016.

Belen Garijo, 54, will take over leadership of the entire pharma business, according to the statement. Garijo is already CEO of Merck’s biopharmaceutical division, Merck Serono, to which she will add consumer health, allergy treatments and biosimilars.

(Reporting by Georgina Prodhan; Editing by Ludwig Burger)

Read the original here:
feeds.reuters

Healthy Living News From around The Web
Merck KGaA appoints pharma head Stefan Oschmann as deputy CEO - Economic Times




Google+

Dopps Chiropractic
4746 S. Broadway
Wichita, Ks 67216
(316) 522-1122
http://ift.tt/14R1IJ3

Merck KGaA appoints pharma head Oschmann as deputy CEO



Merck KGaA appoints pharma head Oschmann as deputy CEO

(Reuters) – German drugs and chemicals maker Merck KGaA appointed the head of its pharma business, Stefan Oschmann, as deputy chief executive, it said on Thursday.

Oschmann, 57, will share strategic management functions and representation of the company with CEO Karl-Ludwig Kley as of Jan. 1, 2015, it said.

The promotion puts Oschmann in the frame to possibly succeed Kley, whose contract runs until September 2016.

Belen Garijo, 54, will take over leadership of the entire pharma business, according to the statement. Garijo is already CEO of Merck’s biopharmaceutical division, Merck Serono, to which she will add consumer health, allergy treatments and biosimilars.

(Reporting by Georgina Prodhan; Editing by Ludwig Burger)

Read the original here:
feeds.reuters

Healthy Living News From around The Web
Merck KGaA appoints pharma head Stefan Oschmann as deputy CEO - Economic Times




Google+

Dopps Chiropractic
7130 W. Maple Suite 200
Wichita, Ks 67209
(316) 944-2020
http://ift.tt/14R1IIT

Text
Photo
Quote
Link
Chat
Audio
Video